Wall Street brokerages forecast that Intrexon Corp (NYSE:XON) will announce ($0.31) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Intrexon’s earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.35). Intrexon posted earnings per share of ($0.26) during the same quarter last year, which suggests a negative year over year growth rate of 19.2%. The company is expected to issue its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Intrexon will report full-year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($0.99). For the next year, analysts anticipate that the business will post earnings of ($0.89) per share, with EPS estimates ranging from ($1.00) to ($0.72). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Intrexon.
Several brokerages have recently issued reports on XON. Northland Securities restated a “buy” rating and issued a $27.00 price objective on shares of Intrexon in a research note on Friday, October 6th. Griffin Securities restated a “buy” rating and issued a $55.00 price objective on shares of Intrexon in a research note on Friday, October 6th. JMP Securities reiterated an “outperform” rating and set a $42.00 price target on shares of Intrexon in a research note on Thursday, October 5th. Zacks Investment Research downgraded shares of Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Stifel Nicolaus lifted their price target on shares of Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $38.50.
A number of institutional investors and hedge funds have recently bought and sold shares of XON. Vanguard Group Inc. boosted its stake in Intrexon by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after buying an additional 147,517 shares in the last quarter. Commonwealth Equity Services Inc boosted its stake in Intrexon by 660.7% during the third quarter. Commonwealth Equity Services Inc now owns 158,089 shares of the biotechnology company’s stock worth $3,005,000 after buying an additional 137,307 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in Intrexon by 25.3% during the third quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock worth $11,089,000 after buying an additional 117,605 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Intrexon during the third quarter worth $1,945,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Intrexon by 7,504.8% during the third quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after acquiring an additional 58,838 shares during the period. Hedge funds and other institutional investors own 77.45% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/04/intrexon-corp-xon-expected-to-announce-earnings-of-0-31-per-share.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.